Canopy Growth (WEED) 주식 개요
캐노피 그로스 코퍼레이션은 자회사와 함께 주로 미국, 캐나다, 독일 및 국제적으로 레크리에이션 및 의료 목적으로 대마초 및 대마 기반 제품의 생산, 유통 및 판매에 종사하고 있습니다. 자세히 보기
WEED Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Canopy Growth Corporation 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | CA$1.49 |
| 52주 최고가 | CA$3.28 |
| 52주 최저가 | CA$1.18 |
| 베타 | 2.39 |
| 1개월 변동 | -4.49% |
| 3개월 변동 | -9.15% |
| 1년 변동 | -44.61% |
| 3년 변동 | -87.69% |
| 5년 변동 | -99.50% |
| IPO 이후 변동 | -94.25% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 13
WEED: Expanded Product Line And Equity Raise Will Drive Future Upside
Analysts have modestly reduced their price target on Canopy Growth to CA$2.38, citing slightly higher assumed discount rates, a somewhat stronger profit margin outlook, and a lower future P/E multiple in their refreshed models. What's in the News Canopy Growth and its medical brand Spectrum Therapeutics expanded their Minor Cannabinoid softgel lineup, adding new 30 and 90 pack formats and more dosing options across the Optimized Spectrum portfolio for both daytime and nighttime use (Key Developments).
내러티브 업데이트 • Apr 26
WEED: New Brand Launch And Equity Raise Will Support Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from CA$5.00 to CA$4.82, citing updated assumptions that include a slightly lower revenue growth outlook, a higher profit margin and a reduced future P/E multiple. What's in the News Canopy Growth launched Deelish, a new cannabis brand aimed at everyday consumers, with products positioned at everyday price points and high THC content across both flower and pre-roll formats (Key Developments).내러티브 업데이트 • Apr 11
WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside
Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.Recent updates
내러티브 업데이트 • May 13
WEED: Expanded Product Line And Equity Raise Will Drive Future Upside
Analysts have modestly reduced their price target on Canopy Growth to CA$2.38, citing slightly higher assumed discount rates, a somewhat stronger profit margin outlook, and a lower future P/E multiple in their refreshed models. What's in the News Canopy Growth and its medical brand Spectrum Therapeutics expanded their Minor Cannabinoid softgel lineup, adding new 30 and 90 pack formats and more dosing options across the Optimized Spectrum portfolio for both daytime and nighttime use (Key Developments).내러티브 업데이트 • Apr 26
WEED: New Brand Launch And Equity Raise Will Support Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from CA$5.00 to CA$4.82, citing updated assumptions that include a slightly lower revenue growth outlook, a higher profit margin and a reduced future P/E multiple. What's in the News Canopy Growth launched Deelish, a new cannabis brand aimed at everyday consumers, with products positioned at everyday price points and high THC content across both flower and pre-roll formats (Key Developments).내러티브 업데이트 • Apr 11
WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside
Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.내러티브 업데이트 • Mar 28
WEED: Term Loan Refinancing Will Support Medical Expansion And New Formats
Analysts have reduced their Canopy Growth fair value estimate from CA$3.20 to about CA$2.38, citing updated assumptions around revenue growth, profit margins, the discount rate, and a lower expected future P/E multiple. What's in the News Canopy Growth filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at $1.03 each (Key Developments).내러티브 업데이트 • Mar 13
WEED: Term Loan And Equity Raise Will Support Future Acquisitions
Analysts have trimmed their CA$ price target on Canopy Growth, citing slightly higher projected revenue growth, a lower profit margin outlook, and a higher assumed future P/E multiple. Together, these factors imply a more cautious stance on the shares.내러티브 업데이트 • Feb 26
WEED: Term Loan And Equity Raise Will Support Future Portfolio Expansion
Analysts have adjusted their price target on Canopy Growth to CA$5.00, reflecting updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What's in the News Filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at about $1.03 per share (Key Developments).내러티브 업데이트 • Feb 11
WEED: Term Loan Funding Will Support Expansion Of Medical And Adult-Use Portfolio
Analysts have trimmed their fair value estimate for Canopy Growth from $8.00 to $5.00, citing higher assumed revenue growth of 14.73% paired with much thinner profit margins of 4.78% and a very large 137.82x future P/E, which together point to a riskier and more expensive earnings profile. What's in the News Canopy Growth entered a term loan agreement to receive net proceeds of US$150 million from lenders led by JGB Management Inc., with the loan maturing in January 2031.내러티브 업데이트 • Jan 27
WEED: Medical Expansion And New Product Formats Will Drive Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from US$3.76 to about US$3.20. This reflects updated assumptions around slower revenue growth, a slightly lower future P/E, and a broadly unchanged margin and discount rate profile.분석 기사 • Jan 11
More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 28%
Canopy Growth Corporation ( TSE:WEED ) shares have had a horrible month, losing 28% after a relatively good period...내러티브 업데이트 • Jan 11
WEED: Medical And Adult Use Product Expansion Will Drive Future Upside
Analysts have made only very small tweaks to their inputs for Canopy Growth, keeping the fair value estimate steady at $3.76 while slightly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these changes support a largely unchanged price target outlook.내러티브 업데이트 • Dec 23
WEED: Medical Expansion Will Drive Future Upside For Shares
Analysts have nudged their price target on Canopy Growth higher to reflect an improved fair value estimate, rising from approximately $3.30 to $3.76. This revision is supported by slightly stronger projected revenue growth, a notable uplift in expected profit margins, and a lower anticipated future price to earnings multiple.내러티브 업데이트 • Dec 08
WEED: Medical Expansion And Share Consolidation Will Drive Future Upside
Analysts have modestly adjusted their price target on Canopy Growth, citing largely unchanged assumptions for fair value at approximately 3.30 dollars, a stable discount rate near 6.12 percent, and essentially flat outlooks for revenue growth, profit margins, and future valuation multiples. What's in the News Launched Claybourne Gassers All in One vapes featuring high potency liquid diamonds and anti clog, anti burn technology, along with new Claybourne Frosted Flyers infused pre roll variety packs in select Canadian regions and online medical channels (Key Developments) Expanded the Spectrum Therapeutics portfolio in Australia with new CBD, THC, and balanced softgel capsules, deepening the company’s presence in the maturing Australian medical cannabis market (Key Developments) Shareholders approved amendments to the company’s articles to allow a potential consolidation of common and exchangeable shares, giving the board discretionary authority to implement a reverse split within 12 months (Key Developments) Transitioned the DOJA facility in Kelowna, British Columbia, into an exclusive medical cultivation site under a micro cultivation license, focused on small batch craft cannabis for Spectrum Therapeutics patients, including veterans (Key Developments) Appointed Tom Stewart as permanent Chief Financial Officer, formalizing his role after serving as interim CFO and leading efforts to stabilize the balance sheet, cut expenses, and improve liquidity (Key Developments) Valuation Changes Fair Value: Unchanged at approximately CA$3.30 per share, indicating no material revision to intrinsic value estimates.내러티브 업데이트 • Nov 24
WEED: Improving Profit Margins And Share Consolidation Will Drive Future Upside
Analysts have raised their price target for Canopy Growth from $1.30 to $3.30. They cite improvements in profit margin projections and expectations of sustained profitability, despite moderated revenue growth forecasts.분석 기사 • Nov 15
Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Canopy Growth Corporation ( TSE:WEED ) shares have had a horrible month, losing 26% after a relatively good period...분석 기사 • Nov 10
Canopy Growth Corporation (TSE:WEED) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Canopy Growth Corporation ( TSE:WEED ) released its second-quarter result to the...내러티브 업데이트 • Nov 10
WEED: Rising Discount Rate Will Pressure Share Price In The Months Ahead
Analysts have adjusted their price target for Canopy Growth downward from $2.64 to $1.30. They cited an increased discount rate as well as ongoing evaluations of profit margin and future earnings potential.분석 기사 • Aug 30
Revenues Tell The Story For Canopy Growth Corporation (TSE:WEED) As Its Stock Soars 70%
Canopy Growth Corporation ( TSE:WEED ) shares have had a really impressive month, gaining 70% after a shaky period...내러티브 업데이트 • Aug 07
European Expansion And Operational Improvements Will Unlock Cannabis Potential
Consensus analyst price targets for Canopy Growth have been revised lower primarily due to a marked slowdown in forecast revenue growth, resulting in a fair value decrease from CA$3.31 to CA$2.98. What's in the News Canopy Growth introduced its Canadian-grown 7ACRES brand in Australia, expanding its medical cannabis portfolio with high-THC sativa strains Ultra Jack and Jack Frost.분석 기사 • May 18
Investors Appear Satisfied With Canopy Growth Corporation's (TSE:WEED) Prospects As Shares Rocket 40%
Those holding Canopy Growth Corporation ( TSE:WEED ) shares would be relieved that the share price has rebounded 40% in...분석 기사 • Apr 02
What You Can Learn From Canopy Growth Corporation's (TSE:WEED) P/S After Its 28% Share Price Crash
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 28% in the last...
새로운 내러티브 • Mar 31
New Medical Cannabis And Vaporizer Offerings Will Expand Global Markets
Growth in the medical cannabis sector and product innovation in adult-use and premium vaporizers position Canopy for revenue and market share expansion.분석 기사 • Feb 12
Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 26% in the last...분석 기사 • Dec 22
Canopy Growth Corporation's (TSE:WEED) Popularity With Investors Under Threat As Stock Sinks 26%
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 26% in the last...분석 기사 • Nov 05
Canopy Growth Corporation (TSE:WEED) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Canopy Growth Corporation ( TSE:WEED ) shareholders are no doubt pleased to see that the share price has bounced 28% in...분석 기사 • Aug 28
More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 26%
To the annoyance of some shareholders, Canopy Growth Corporation ( TSE:WEED ) shares are down a considerable 26% in the...분석 기사 • Aug 17
We Think Canopy Growth (TSE:WEED) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jun 15
Some Confidence Is Lacking In Canopy Growth Corporation (TSE:WEED) As Shares Slide 26%
Canopy Growth Corporation ( TSE:WEED ) shares have retraced a considerable 26% in the last month, reversing a fair...주주 수익률
| WEED | CA Pharmaceuticals | CA 시장 | |
|---|---|---|---|
| 7D | 0.7% | -3.6% | -0.07% |
| 1Y | -44.6% | 45.6% | 33.7% |
수익률 대 산업: WEED은 지난 1년 동안 45.6%의 수익을 기록한 Canadian Pharmaceuticals 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: WEED은 지난 1년 동안 33.7%를 기록한 Canadian 시장보다 저조한 성과를 냈습니다.
주가 변동성
| WEED volatility | |
|---|---|
| WEED Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.9% |
안정적인 주가: WEED는 지난 3개월 동안 Canadian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: WEED의 주간 변동성(11%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| n/a | 960 | Luc Mongeau | www.canopygrowth.com |
캐노피 그로스 코퍼레이션은 자회사와 함께 주로 미국, 캐나다, 독일 및 국제적으로 레크리에이션 및 의료 목적으로 대마초 및 대마 기반 제품의 생산, 유통 및 판매에 종사하고 있습니다. 캐나다 대마초, 인터내셔널 마켓 대마초, 스토어즈 앤 비켈 부문을 통해 운영되고 있습니다. 이 회사는 말린 꽃, 미리 말린 관절, 오일, 소프트젤 캡슐, 주입식 음료, 구미로 구성된 식용 제품, 국소 제형 및 기화기 장치를 제공합니다.
Canopy Growth Corporation 기초 지표 요약
| WEED 기초 통계 | |
|---|---|
| 시가총액 | CA$544.57m |
| 순이익 (TTM) | -CA$327.29m |
| 매출 (TTM) | CA$278.39m |
2.0x
주가매출비율(P/S)-1.7x
주가수익비율(P/E)WEED는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| WEED 손익계산서 (TTM) | |
|---|---|
| 매출 | CA$278.39m |
| 매출원가 | CA$204.45m |
| 총이익 | CA$73.94m |
| 기타 비용 | CA$401.24m |
| 순이익 | -CA$327.29m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
Jun 15, 2026
| 주당순이익(EPS) | -0.86 |
| 총이익률 | 26.56% |
| 순이익률 | -117.57% |
| 부채/자본 비율 | 29.7% |
WEED의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 20:10 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Canopy Growth Corporation는 23명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |